var data={"title":"Liotrix: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liotrix: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6469?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liotrix-drug-information\" class=\"drug drug_general\">see &quot;Liotrix: Drug information&quot;</a> and <a href=\"topic.htm?path=liotrix-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liotrix: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709014\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Weight reduction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Drugs with thyroid hormone activity, alone or with other therapeutic agents have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189131\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Thyrolar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189132\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Thyrolar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1022260\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Thyroid Product</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14856054\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be adjusted based on clinical response and laboratory parameters</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital hypothyroidism: </b>Oral: Usual daily dosage range: Liothyronine (T<sub>3</sub>): 3.1 to 6.25 mcg; levothyroxine (T<sub>4</sub>): 12.5 to 25 mcg once daily. <b>Note:</b> AAP recommends levothyroxine as the preferred treatment for hypothyroidism in neonates (AAP 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1022287\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=liotrix-drug-information\" class=\"drug drug_general\">see &quot;Liotrix: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be adjusted based on clinical response and laboratory parameters; guidelines do not recommend routine use of levothyroxine/liothyronine combinations over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Congenital hypothyroidism:</b><b> Note:</b> Infants should have therapy initiated at full doses. Oral: Usual daily dosage range:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &le;6 months: Liothyronine (T<sub>3</sub>): 3.1 to 6.25 mcg/levothyroxine (T<sub>4</sub>): 12.5 to 25 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;6 to 12 months: Liothyronine (T<sub>3</sub>): 6.25 to 9.35 mcg/levothyroxine (T<sub>4</sub>): 25 to 37.5 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 5 years: Liothyronine (T<sub>3</sub>): 9.35 to 12.5 mcg/levothyroxine (T<sub>4</sub>): 37.5 to 50 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 12 years: Liothyronine (T<sub>3</sub>): 12.5 to 18.75 mcg/levothyroxine (T<sub>4</sub>): 50 to 75 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Typical doses &gt; Liothyronine (T<sub>3</sub>): 18.75 mcg; levothyroxine (T<sub>4</sub>): 75 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Hypothyroidism:</b> Oral: Initial: Liothyronine (T<sub>3</sub>) 6.25 mcg/levothyroxine (T<sub>4</sub>) 25 mcg once daily. A lower initial dose (liothyronine 3.1 mcg/levothyroxine 12.5 mcg) is recommended in patients with long-standing myxedema, especially if cardiovascular impairment coexists. If angina occurs, reduce dose. Dose may be increased by liothyronine 3.1 mcg/levothyroxine 12.5 mcg every 2 to 3 weeks. Usual maintenance dose: Liothyronine 12.5 to 25 mcg/levothyroxine 50 to 100 mcg once daily; inadequate response despite adequate dosage replacement may indicate nonadherence, poor absorption, excessive elimination, or inactivity of the preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189112\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrolar: <sup>1</sup>/<sub>4</sub> [levothyroxine sodium 12.5 mcg and liothyronine sodium 3.1 mcg]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrolar: <sup>1</sup>/<sub>2</sub> [levothyroxine sodium 25 mcg and liothyronine sodium 6.25 mcg]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrolar: 1 [levothyroxine sodium 50 mcg and liothyronine sodium 12.5 mcg]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrolar: 2 [levothyroxine sodium 100 mcg and liothyronine sodium 25 mcg]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrolar: 3 [levothyroxine sodium 150 mcg and liothyronine sodium 37.5 mcg]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189095\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51192855\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer orally; levothyroxine (a component of liotrix) should be administered consistently on an empty stomach 30 to 60 minutes prior to breakfast.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189127\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1022261\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); pituitary TSH suppressant for the prevention or treatment of various types of euthyroid goiter, thyroid nodules, thyroiditis (Hashimoto's), multinodular goiter, and thyroid cancer (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Clinical practice guidelines do not recommend routine use of levothyroxine/liothyronine combinations over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]) or for TSH suppression in the management in thyroid cancer (ATA [Haugen 2015]). Guidelines do not recommend using TSH suppression for benign thyroid nodules in iodine sufficient patients (ATA [Haugen 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189147\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Liotrix may be confused with Klotrix</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrolar may be confused with Thyrogen</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189146\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, chest pain, increased blood pressure, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, ataxia, headache, insomnia, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Menstrual disease, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, constipation, diarrhea, increased appetite, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia, tremor, tremor of hands</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Allergic skin reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189117\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to liotrix or any component of the formulation; uncorrected adrenal insufficiency; untreated thyrotoxicosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189099\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated; contraindicated in patients with uncorrected adrenal insufficiency. Treatment with glucocorticoids should precede thyroid replacement therapy in patients with adrenal insufficiency (ATA/AACE [Garber 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution and initiate therapy at a lower dose in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated; initial dosage reduction is recommended in patients with long-standing myxedema. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly as these patients are more likely to have compromised cardiovascular function; lower initial dosage is recommended. Suppressed TSH levels may increase risk of atrial fibrillation and mortality secondary to cardiovascular disease (Gharib 2010; Parle 2001). Increase dose slowly and monitor for signs/symptoms of angina (ATA/AACE [Garber 2012]). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infertility (unapproved use): Use is not justified for the treatment of male or female infertility in euthyroid patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Weight reduction (unapproved use):<b>[US Boxed Warning]: In euthyroid patients, thyroid supplements are ineffective and potentially toxic for weight reduction. High doses may produce serious or even life-threatening toxic effects, particularly when used with some anorectic drugs. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022323\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely. May cause transient alopecia in children during first few months of therapy. In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299608\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189104\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87041&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189107\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189120\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liotrix has not been found to increase the risk of adverse effects following maternal use during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1022292\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">T<sub>4</sub>, TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage in primary thyroid dysfunction. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T<sub>4</sub> remains low and TSH is within normal limits, an evaluation of &quot;free&quot; (unbound) T<sub>4</sub> is needed to evaluate further increase in dosage. Free T<sub>4</sub> (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T<sub>4</sub>. During the first 3 years of life, total- or free-T<sub>4</sub> should be maintained in the upper <sup>1</sup>/<sub>2</sub> of the normal range; this should result in normalization of TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of in utero hypothyroidism. Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Suggested frequency for monitoring thyroid function tests: Every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adults: Monitor TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (ATA [Jonklaas 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1022280\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Thyroid Function Tests</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Lab Parameters</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Normal Range</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>4</sub> (thyroxine) serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.1-20.9 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8-14 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.8-16.6 mcg/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 month to 1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.5-16.0 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.0-12.0 mcg/dL </p></td></tr>\n        <tr>\n          <td rowspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">Free thyroxine index (FTI) </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.3-26.6 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 weeks </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.6-20.8 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.4-17.9 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4-12 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.1-14.5 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7-13.3 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.8-14.0  </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Newborns</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-470 ng/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-5 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-260 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-10 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90-240 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 years to Adult </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70-210 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> uptake</p></td>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35%-45% </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">TSH serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Cord</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-22 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;40 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;25 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0-10 micro international units/mL </p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189098\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The primary active compound is T<sub>3</sub> (triiodothyronine), which may be converted from T<sub>4</sub> (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues. Liotrix is uniform mixture of synthetic T<sub>4</sub> and T<sub>3</sub> in 4:1 ratio; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189116\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Liothyronine (T<sub>3</sub>): ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Thyroxine (T<sub>4</sub>): 40% to 80%; T<sub>3</sub>: 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: T<sub>4</sub>: &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to triiodothyronine (active); ~80% T<sub>4</sub> deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T<sub>4</sub>: Euthyroid: 6-7 days; Hyperthyroid: 3-4 days; Hypothyroid: 9-10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T<sub>3</sub>: 2.5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: T<sub>4</sub>: 2-4 hours; T<sub>3</sub>: 2-3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (major route of elimination); partially feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422261\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Thyrolar-1 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 (12.5-50) mg (mcg) (100): $76.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Thyrolar-1/2 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 (6.25-25) mg (mcg) (100): $60.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Thyrolar-1/4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 (3.1-12.5) mg (mcg) (100): $54.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Thyrolar-2 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 (25-100) mg (mcg) (100): $89.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Thyrolar-3 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 (37.5-150) mg (mcg) (100): $109.33</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189121\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Euthyral (VN);</li>\n      <li>Thyreotom (CY, EG, IQ, JO, LY, SY);</li>\n      <li>Thyreotom Forte (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Thyrolar (BB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, &quot;Update of Newborn Screening and Therapy for Congenital Hypothyroidism,&quot; <i>Pediatrics</i>, 2006, 117(6):2290-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liotrix-pediatric-drug-information/abstract-text/16740880/pubmed\" target=\"_blank\" id=\"16740880\">16740880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liotrix-pediatric-drug-information/abstract-text/23246686/pubmed\" target=\"_blank\" id=\"23246686\">23246686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gharib H, Papini E, Paschke R, et al; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. <i>Endocr Pract</i>. 2010;16(suppl 1):1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liotrix-pediatric-drug-information/abstract-text/20497938/pubmed\" target=\"_blank\" id=\"20497938\">20497938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liotrix-pediatric-drug-information/abstract-text/26462967/pubmed\" target=\"_blank\" id=\"26462967\">26462967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. <i>Thyroid</i>. 2014;24(12):1670-1751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liotrix-pediatric-drug-information/abstract-text/25266247/pubmed\" target=\"_blank\" id=\"25266247\">25266247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. <i>Lancet</i>. 2001;358(9285):861-865.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liotrix-pediatric-drug-information/abstract-text/11567699/pubmed\" target=\"_blank\" id=\"11567699\">11567699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thyrolar (liotrix tablets) [prescribing information]. St Louis, MO: Forest Pharmaceuticals, Inc.; January 2010.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87041 Version 51.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709014\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189131\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F189132\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1022260\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F14856054\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1022287\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189112\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189095\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F51192855\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F189127\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1022261\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189147\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189146\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189117\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189099\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022323\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299608\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189104\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F189107\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189120\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1022292\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1022280\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189098\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F189116\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422261\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189121\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/87041|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liotrix-drug-information\" class=\"drug drug_general\">Liotrix: Drug information</a></li><li><a href=\"topic.htm?path=liotrix-patient-drug-information\" class=\"drug drug_patient\">Liotrix: Patient drug information</a></li></ul></div></div>","javascript":null}